Post A Reply
Allstocks.com's Bulletin Board
Hot Stocks Free for All !
» Post A Reply
Post A Reply
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by Peaser: [QB] MannKind Corporation Announces Termination of License and Collaboration Agreement With Sanofi 9:00 am ET January 5, 2016 (Globe Newswire) Print MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced the termination of its license and collaboration agreement with sanofi-aventis U.S. LLC for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The parties will promptly commence transition discussions in order to effect a smooth and orderly transition in the development and commercialization of Afrezza from Sanofi to MannKind over the next 90 - 180 days. In any event, termination of the license agreement in its entirety will be effective no later than six months from the effective date of Sanofi's notice of termination, or July 4, 2016. MannKind is reviewing its strategic options for Afrezza as a result of the termination of the collaboration with Sanofi. MannKind will host a conference call at 4:30 pm (Eastern Time) on January 5, 2016. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 4155 4306. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4155 4306#. A replay will also be available on MannKind's website for 14 days. About MannKind Corporation MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website. Company Contact: Matthew J. Pfeffer Corporate Vice President and Chief Financial Officer (661) 775-5300 email@example.com [URL=http://resource.globenewswire.com/Resource/Download/879918a6-2885-4a9e-8ef5-7acd42356e45?size=1]http://resource.globenewswire.com/Resource/Download/879918a6-2885-4a9e-8ef5-7acd 42356e45?size=1[/URL] [/QB][/QUOTE]
Instant UBB Code™
What is UBB Code™?
Disable Graemlins in this post.
*** Click here to review this topic. ***
Allstocks.com Message Board Home
© 1997 - 2018 Allstocks.com. All rights reserved.